Eksigent increases HPLC manufacturing capacity by 40%
Eksigent Technologies, a US provider of advanced low-flow fluid delivery technologies for drug discovery and other life science applications, is to increase manufacturing capacity in California by 40% to meet strong demand for its HPLC products.
Eksigent Technologies, a US provider of advanced low-flow fluid delivery technologies for drug discovery and other life science applications, is to increase manufacturing capacity in California by 40% to meet strong demand for its HPLC products.
"The need for this increase in product build capability is being driven by higher than expected customer demand for both our cHiPLC-nanoflex for proteomics and our ExpressHT-Ultra HPLC system for ADME-Tox and DMPK studies," said David Neyer, vice president and co-founder of Eksigent.
The company is also recruiting field service staff to ensure that customer installations are maintained with short lead times.
Eksigent's Board of Directors has approved spending for additional equipment, tools and staff.
The cHiPLC-nanoflex system is a docking station for up to three microfluidic chips that contain nanoLC or trap columns. It delivers improved reproducibility and ease of use to proteomics research, the company says.
The ExpressHT-Ultra HPLC system for small molecule analysis provides short cycle times and high throughput for LC/MS studies of pharmacokinetics and drug metabolism.